Beschrijving:

SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Trefwoorden:

Clinical Trial

Off-Treatment

C50-C50.9

26-08-12 26-08-12 -
09-01-15 09-01-15 - Martin Dugas

Geüploaded op:

9 januari 2015

DOI:

Voor een aanvraag inloggen.

Licentie :

Creative Commons BY-NC 3.0 Legacy

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Breast Cancer NCT00127205 Off Treatment - SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) - 2287059v3.0

Details

No Instruction available.

1 Formulieren

StudyEvent: SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307)
1. No Instruction available.

Header

SWOG Patient ID

SWOG Study No.

Registration Step

Patient Initials (L, F M)

Institution/Affiliate

Physician

Participating Group Name

Participating Group Study No.

Participating Group Patient ID (Instructions: Submit this form after completion of end-of-study bone scan. If bone scan was not done, explain in Comments. All dates are MONTH, DAY, YEAR. Explain any blank fields or blank dates in the Comments section. Place an X in appropriate boxes. Circle AMENDED items in red and write AMENDED across top of form.)

Bone Scan

Did the patient have a bone scan after completion or discontinuation of protocol therapy?

Yes

date of bone scan (If yes,)

Bone metastases?

Yes

Patient Preference

If oral and intravenous bisphosphonates are equally effective in preventing breast cancer recurrence in the bone, which would the patient prefer to receive?

Oral (Oral)

Intravenous (Intravenous)

Comments

Terug naar het begin van de pagina

Similar models

Show recommended models